Ann: Notice of Extraordinary General Meeting/Proxy Form, page-3

Up to 100m extra shares .

Between $20m and $30m into the coffers , assuming .20c to .30c
Hopefully that’s it for dilution.
Plenty there to successfully launch Conneqt with added cash flow from Pulse sales, trial revenue etc
Craig reckons cash flow positive in 2 years on projections.

When all is said and done, including options, convertible notes etc will have around 300m SOI ( yet to do the maths, a guesstimate).

So what will the value of an entity that owns vascular biomarkers derived from non-invasive CBP readings with approved FDA device for decentralised trials, remote patient monitoring and at-home prescribed use be worth. Then add the Conneqt band, more customers licensing the tech , moving to OTC for Pulse in 18 months, owning FDA approved digital biomarkers for the likes of alzheimers and kidney function , etc etc

Divide you answer by 300m.
I get a very large multiple if you can hang around for a while.